Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CCR1 | P32246 | 9/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476793 | 0.86 | CYP1A2 (0.51) | CYP17A1CYP1A2MKNK1MKNK2MAPK14 | |
| SCHEMBL4573821 | 0.86 | MAPK14 (0.50) | CYP17A1CYP1A2CCR1MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL304059 | 0.85 | CYP1A2 (0.50) | CYP17A1CYP1A2MKNK1MKNK2MAPK14 | |
| SCHEMBL25257558 | 0.84 | XDH (0.53) | CYP17A1CYP1A2CCR1MKNK1MKNK2 | |
| SCHEMBL30491768 | 0.84 | XDH (0.53) | CYP17A1CYP1A2CCR1MKNK1MKNK2 | |
| SCHEMBL4572945 | 0.84 | MKNK1 (0.47) | CYP17A1CYP1A2CCR1MKNK1MKNK2 | |
| SCHEMBL305462 | 0.83 | CYP1A2 (0.49) | CYP17A1CYP1A2CCR1MKNK1MKNK2 | |
| SCHEMBL441028 | 0.82 | CYP1A2 (0.54) | CYP17A1CYP1A2CCR1NR3C1PGR | |
| SCHEMBL443587 | 0.82 | CYP1A2 (0.54) | CYP17A1CYP1A2CCR1NR3C1PGR | |
| SCHEMBL4113695 | 0.82 | CYP17A1 (0.54) | CYP17A1CYP1A2CCR1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869003-B1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| EP-1869003-B1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| EP-2081910-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| EP-2081910-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| EP-1940800-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008055709-A1 | INDAZOLE AND INDOLE DERIVATIVES AS ANTI -INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921068-A1 | Indazole and indole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008052808-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1917963-A1 | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008043789-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043789-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| EP-1869003-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007046747-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006108699-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |